Compare AbCellera Biologics Inc (ABCL) vs Monolithic Power Systems Inc (MPWR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Monolithic Power Systems Inc — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while Monolithic Power Systems Inc trades at $1,320.9 (market cap $62.53B). The key difference: Monolithic Power Systems Inc is far larger — about 26.6× AbCellera Biologics Inc's market cap, and Monolithic Power Systems Inc pays a 0.63% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MPWR | |
|---|---|---|
Market Cap | $2.35B | $62.53B |
Sector | Health | Utilities |
52-Week High | $8.12 | $1.69K |
52-Week Low | $2.78 | $711.24 |
Enterprise Value | $1.99B | $61.19B |
Dividend Yield | — | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
MPWR trades at $1,346.13, up 4.5% in the past 24 hours, showing strong momentum. The stock exhibits bearish technical signals but benefits from consistent earnings beats and robust profitability, with a net margin of 22.98%. Recent news highlights growth in AI infrastructure and consumer electronics demand. Cash flow remains positive, and a $2.00 dividend is scheduled for July 2026.
Outlook is supported by analyst optimism (88% buy ratings) and a consensus price target of $1,760, though high valuation multiples and ongoing legal investigations pose risks. Revenue growth and AI-driven demand present opportunities, but investors should weigh elevated P/E of 96.36 against potential market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →
